BR112021025764A2 - Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo - Google Patents

Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo

Info

Publication number
BR112021025764A2
BR112021025764A2 BR112021025764A BR112021025764A BR112021025764A2 BR 112021025764 A2 BR112021025764 A2 BR 112021025764A2 BR 112021025764 A BR112021025764 A BR 112021025764A BR 112021025764 A BR112021025764 A BR 112021025764A BR 112021025764 A2 BR112021025764 A2 BR 112021025764A2
Authority
BR
Brazil
Prior art keywords
growth
present
cancer cells
inhibits
provides
Prior art date
Application number
BR112021025764A
Other languages
English (en)
Inventor
Hyung-Chul Ryu
Jae-Sun Kim
Sun-Ho Lee
Sung-Eun Kim
Yong-Hyub Lee
Original Assignee
Oncobix Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobix Co Ltd filed Critical Oncobix Co Ltd
Publication of BR112021025764A2 publication Critical patent/BR112021025764A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo. a presente invenção fornece novos compostos derivados de pirimidina que inibem o crescimento de células cancerígenas e sais farmaceuticamente aceitáveis dos mesmos. a presente invenção fornece uma composição farmacêutica compreendendo esses compostos ou sais farmaceuticamente aceitáveis. a presente invenção também fornece um uso médico para o tratamento de câncer de pulmão, distinguido pelo uso desses compostos derivados de pirimidina e sais farmaceuticamente aceitáveis dos mesmos como um ingrediente ativo. a presente invenção também fornece um método para o tratamento de câncer de pulmão, compreendendo a administração de uma dose eficaz de compostos de acordo com a presente invenção, sais dos mesmos ou uma composição que os compreende.
BR112021025764A 2019-06-20 2020-06-19 Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo BR112021025764A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20190073345 2019-06-20
PCT/KR2020/007982 WO2020256477A1 (ko) 2019-06-20 2020-06-19 암 세포 성장을 억제하는 피리미딘 유도체 및 이의 의약 용도

Publications (1)

Publication Number Publication Date
BR112021025764A2 true BR112021025764A2 (pt) 2022-02-01

Family

ID=74040576

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025764A BR112021025764A2 (pt) 2019-06-20 2020-06-19 Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo

Country Status (10)

Country Link
US (1) US20220227781A1 (pt)
EP (1) EP3988542A4 (pt)
JP (1) JP7330546B6 (pt)
KR (1) KR102510072B1 (pt)
CN (1) CN114008028A (pt)
AU (1) AU2020296620B2 (pt)
BR (1) BR112021025764A2 (pt)
CA (1) CA3143919A1 (pt)
MX (1) MX2021015543A (pt)
WO (1) WO2020256477A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113717156B (zh) * 2020-05-25 2023-05-09 南京红云生物科技有限公司 Egfr抑制剂、其制备方法及用途
US20240051940A1 (en) * 2021-02-08 2024-02-15 Accutar Biotechnology Inc. Sulfonamides with egfr inhibition activities and their use thereof
CN117203199A (zh) * 2021-04-02 2023-12-08 毕利吉生物科技股份有限公司 N2-苯基嘧啶-2,4-二胺化合物及其制备方法和使用方法
KR102611488B1 (ko) * 2021-08-05 2023-12-11 한국화학연구원 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
AU2022322671A1 (en) * 2021-08-05 2024-02-29 Industry-Academic Cooperation Foundation, Yonsei University Pyrimidine derivative, method for preparing same, and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2659725T3 (es) * 2009-05-05 2018-03-19 Dana-Farber Cancer Institute, Inc. Inhibidores de EGFR y procedimiento de tratamiento de trastornos
CN105188371A (zh) * 2013-02-08 2015-12-23 西建阿维拉米斯研究公司 Erk抑制剂及其用途
CN106559991B (zh) 2014-06-19 2019-09-20 阿里亚德医药股份有限公司 用于激酶抑制的杂芳基化合物
US10106507B2 (en) * 2014-08-03 2018-10-23 H. Lee Moffitt Cancer Center and Research Insitute, Inc. Potent dual BRD4-kinase inhibitors as cancer therapeutics
EP3205650B1 (en) 2014-10-11 2021-08-04 Shanghai Hansoh Biomedical Co., Ltd. Egfr inhibitor, and preparation and application thereof
CN105085489B (zh) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016183278A1 (en) 2015-05-13 2016-11-17 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN106187915A (zh) * 2015-05-27 2016-12-07 上海翰森生物医药科技有限公司 具有alk与egfr双重活性的抑制剂及其制备方法和应用
JP6606278B2 (ja) 2015-08-31 2019-11-13 ウーシー ショアンリャン バイオテクノロジー カンパニー，リミティド ２−アリールアミノピリジン、ピリミジン又はトリアジン誘導体及びその製造方法と使用
AU2016362390B2 (en) 2015-12-03 2021-11-11 Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. Thieno-pyrimidine derivatives and uses thereof
JOP20190281A1 (ar) * 2017-06-13 2019-12-02 Korea Res Inst Chemical Tech مشتق n2، n4 ثنائي فينيل بيريميدين -2، 4- ثنائي أمين، وطريقة لتحضيره، وتركيبة صيدلانية تحتوي على المشتق بوصفه مكون فعال للوقاية من السرطان أو علاجه
WO2019112344A1 (ko) 2017-12-07 2019-06-13 주식회사 온코빅스 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
CN114105887B (zh) * 2021-09-16 2023-12-01 沈阳药科大学 一种氨基嘧啶衍生物及其制备方法和用途

Also Published As

Publication number Publication date
EP3988542A4 (en) 2023-06-28
AU2020296620A1 (en) 2022-02-17
AU2020296620B2 (en) 2023-07-13
JP7330546B2 (ja) 2023-08-22
JP2022538014A (ja) 2022-08-31
KR102510072B1 (ko) 2023-03-14
KR20200145833A (ko) 2020-12-30
CN114008028A (zh) 2022-02-01
MX2021015543A (es) 2022-04-25
US20220227781A1 (en) 2022-07-21
CA3143919A1 (en) 2020-12-24
JP7330546B6 (ja) 2024-02-21
WO2020256477A1 (ko) 2020-12-24
EP3988542A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
CL2023001738A1 (es) Inhibidores de prmt5
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
EA201992543A1 (ru) Производные пиролопиримидина, пригодные в качестве ингибиторов репликации вируса гриппа
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112019007863A2 (pt) derivados de naftiridinona inovadores e seu uso no tratamento de arritmia
BR112018073419A2 (pt) combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
BR112022024937A2 (pt) Composto de alquenilpirimidina, método de preparação do mesmo, e aplicação do mesmo
BR112023004354A2 (pt) Compostos derivados de sulfamato para uso no tratamento ou alívio de um transtorno psiquiátrico